Advanced Peer Research
Peers Analysis
| Company |
Price |
P/E |
EPS |
Marcap |
1 Yr performance |
52W Low - High |
52W Low - High range |
Valuation |
| Amgen Inc. |
$
269.12 |
26.10 |
10.31 |
152,820 |
-5.76 % |
214.27 - 286.88 |
|
Overvalued |
| AstraZeneca PLC |
$
10,122.00 |
7,128.17 |
1.42 |
15,689,100 |
-10.55 % |
101.80 - 12,294.00 |
|
Undervalued |
| Bayer AG |
€
31.90 |
8.35 |
3.82 |
31,339 |
-39.50 % |
30.56 - 62.49 |
|
Undervalued |
| Biogen Inc. |
$
239.29 |
31.24 |
7.66 |
36,028 |
-17.23 % |
222.59 - 318.06 |
|
Overvalued |
| Gilead Sciences Inc. |
$
79.02 |
56.44 |
1.40 |
98,775 |
-11.68 % |
73.27 - 88.75 |
|
Overvalued |
| GlaxoSmithKline plc |
£
35.94 |
15.69 |
2.29 |
90,569 |
-1.80 % |
33.50 - 38.32 |
|
Undervalued |
| Grifols S.A. |
€
14.19 |
21.83 |
0.65 |
5,991 |
42.18 % |
8.41 - 14.35 |
|
Undervalued |
| Johnson & Johnson Inc. |
$
154.42 |
18.32 |
8.43 |
406,125 |
-12.86 % |
145.60 - 180.25 |
|
Undervalued |
